1-6 of 6
Keywords: glucagon-like peptide-1
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Clin Sci (Lond) (2018) 132 (15): 1699–1709.
Published: 16 August 2018
... for preventing microvascular complications, but the extent to which it can reduce CV complications is less certain. Glucagon-like peptide-1 (GLP-1) agonists are potent glucose-lowering agents but also have potentially beneficial effects on other traditional (body weight, blood pressure (BP), and LDL cholesterol...
Clin Sci (Lond) (2015) 129 (5): 405–414.
Published: 11 June 2015
.... In addition, it was recently reported that short-term exposure to GCs reduced the insulinotropic effects of the incretin GLP-1 (glucagon-like peptide 1). However, although defective GLP-1 secretion has been correlated with insulin resistance, potential direct effects of GCs on GLP-1-producing L-cell function...
Includes: Supplementary data
Clin Sci (Lond) (1999) 96 (4): 335–342.
Published: 01 April 1999
...-dependent insulinotropic polypeptide or glucagon-like peptide-1 (GLP-1). These findings therefore provide no support for the hypothesis that overactivity of the entero-insular axis contributes to the hyperinsulinaemia seen in obesity. Indeed, the plasma GLP-1 response to carbohydrate was markedly attenuated...
Clin Sci (Lond) (1997) 93 (4): 343–347.
Published: 01 October 1997
...Rousseau Gama; Fiona Norris; Linda Morgan; Shelagh Hampton; John Wright; Vincent Marks 1. We investigated whether abnormalities of gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (7–36 amide) (GLP-1) contribute to the hypertriglyceridaemia and hyperinsulinaemia...